Objective-Smooth muscle cell (SMC) differentiation is a dynamic process that must be tightly regulated for proper vascular development and to control the onset of vascular disease. Our laboratory previously reported that a specific focal adhesion kinase (FAK) inhibitor termed FRNK (FAK Related Non-Kinase) is selectively expressed in large arterioles when SMCs are transitioning from a synthetic to contractile phenotype and that FRNK inhibits FAKdependent SMC proliferation and migration. Herein, we sought to determine whether FRNK expression modulates SMC phenotypes in vivo. Methods and Results-We present evidence that FRNK Ϫ/Ϫ mice exhibit attenuated SM marker gene expression during postnatal vessel growth and after vascular injury. We also show that FRNK expression is regulated by transforming growth factor (TGF)-␤ and that forced expression of FRNK in cultured cells induces serum-and TGF-␤-stimulated SM marker gene expression, whereas FRNK deletion or expression of a constitutively activated FAK variant attenuated SM gene transcription.
W hile medial smooth muscle cells (SMCs) found in the mature vessel are fully differentiated and express high levels of SM contractile proteins, these cells do not terminally differentiate and can transition to a synthetic phenotype characterized by low levels of SM contractile gene expression and responsiveness to progrowth and migratory signals. This unique plasticity is critical for proper vessel development, blood pressure homeostasis, and injury repair processes. 1, 2 
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A number of secreted growth factors (ie, platelet derived growth factor [PDGF-BB], sphingosine 1-phosphate [SIP], transforming growth factor-␤ [TGF-␤]) and contractile agonists (angiotensin II, endothelin-1, and thrombin) have been shown to regulate SMC phenotype in vitro and in vivo. 3 In addition to levels of circulating factors, studies have also shown that the extracellular matrix (ECM) that surrounds SMC in the vessel wall can impart control over SM phenotypes. 4 Indeed, genetic ablation of either fibronectin or the ␣ 5 integrin fibronectin receptor results in embryonic lethality associated with impaired SMC investment of both embryonic and extraembryonic vessels. 5, 6 Although the precise signaling mechanisms by which these diverse agonists and ECM regulate SMC transcription have not been completely delineated, several studies indicate that many (but not all) SMspecific genes (particularly contractile genes) depend on the presence of an serum response factor (SRF) DNA binding element termed a CArG box (CC(A/T)6GG), and many of these aforementioned intrinsic factors alter SRF or SRFcofactor activity. 3, [7] [8] [9] [10] One of the major proteins involved in the integrin intracellular signaling cascade is the nonreceptor protein tyrosine kinase, focal adhesion kinase (FAK), which is strongly and rapidly activated by various aforementioned growth factors and by ligation of all ␤ 1 , ␤ 3 , or ␤ 5 containing integrins. 11 Although a direct role for FAK in vascular growth and development has yet to be examined, germline deletion of FAK phenocopies the lethal defects observed in fibronectin Ϫ/Ϫ and ␣ 5 integrin Ϫ/Ϫ embryos. Interestingly, our laboratory recently showed that FAK activity is regulated in a unique fashion in SMCs, whereby a separate protein comprising the carboxyterminus of FAK, termed FRNK (FAK Related Non Kinase), which acts as a dominant-interfering mutant for FAK, is selectively expressed in SMCs with very high levels found in the large arterioles. FRNK transcription results from the use of an alternative start site within the FAK gene, and FRNK expression is independently regulated by a distinct promoter embedded within FAK intronic sequences. 12, 13 Whereas FAK protein levels remain relatively constant during vascular development, FRNK protein levels are dynamically increased in neonatal vessels and in adult vessels two weeks after injury, when SMCs are transitioning from a synthetic to contractile phenotype.
The aim of this study was to determine whether FRNK expression plays a direct role in the phenotypic modulation of SMCs in vivo. Herein we present evidence that FRNK Ϫ/Ϫ mice exhibit repressed SM marker gene expression during postnatal vessel growth and after vascular injury. These data highlight the possibility that extrinsic signals regulate the SMC gene profile by modulating the dynamic expression of FRNK.
Methods
Mice were housed in an AALAC accredited University Animal Care Facility, and all experimental procedures were approved by the University of North Carolina animal care and use committee (IACUC). All quantitative data represent at least 3 separate experiments presented as meanϮSEM. Means were compared by 2-tailed Students t test, and PϽ0.05 was considered statistically significant as indicated by an asterisk. All other data including Western analysis are representative of at least 3 individual experiments. Please see Online Supplemental Data section (available online at http://atvb.ahajournals.org) for a complete description of the animal models, reagents, DNA constructs, and general methods used for these studies.
Results
The 41/43 kDa FRNK protein is selectively expressed in the vasculature from approximately E12.5 onward with highest levels observed in large arterioles and lung of neonatal rats (postnatal day 4 to 14) ( Figure 1B ). 12, 14 FRNK protein was also detected in cells derived from human aorta and coronary arteries and coronary SMC cultures derived from explanted proepicardial organs, but not in cultured endothelial cells (supplemental Figure I ). As previously reported (and depicted in Figure 1A ), FRNK expression is regulated by a promoter embedded within the fak gene and frnk transcription initiates from a noncoding exon located approximately 300 bp upstream of the FRNK translational start site in the mouse gene. 12, 13 Because FRNK shares the same amino acid sequence as the C terminus of FAK, we have been unable to develop a specific antibody that recognizes FRNK (but not FAK) for immunohistochemical analysis of FRNK expression patterns. However, because the frnk noncoding exon is selectively protected in RNA isolated from SMC and SMCcontaining tissues, 12 we developed an in situ probe directed against this unique sequence to examine FRNK expression patterns in vivo. Our in situ analysis of tissues harvested from postnatal day 7 mice revealed that FRNK is expressed throughout the media of large arterial vessels, but is not expressed in either the endothelium or adventitial layer ( Figure 1C , top). Some visceral SMC staining was apparent as well, with high levels observed in the lung ( Figure 1C ) and bladder (not shown). FRNK expression in the lung was localized to the smooth muscle lining of the bronchi in addition to vessels, similar to the staining pattern observed for SM␣-actin. 16 Further analysis of FRNK expression in the developing mouse vasculature using quantitative RT-PQR revealed a dynamic upregulation of FRNK mRNA in aorta between 7 and 10 days postnatal, corroborating our previous Western analysis ( Figure 1D ).
We reasoned that upregulation of FRNK in the neonatal vessels may serve to buffer FAK-dependent signals in this environment that is particularly rich in growth factors and matrices known to be upstream activators of FAK. Thus we sought to identify some of the mechanisms involved in the transient and dynamic regulation of FRNK expression in postnatal vessels. To determine the relative stability of FRNK protein, we treated SMCs with cyclohexamide for various times and analyzed FRNK and FAK levels. In support of the idea that FRNK expression can be tightly regulated, we found that FRNK protein turnover is relatively rapid, with an apparent half-life of approximately 4.5 hour (supplemental Figure IIA ). The level of FAK protein was not significantly changed during the 8-hour time-course examined, consistent with previous reports that FAK protein is extremely stable with a half-life exceeding 20 hours. 26 We next sought to identify factors that can modulate dynamic FRNK expression during vascular morphogenesis. We first used a FRNK promoter reporter construct to define factors that regulate FRNK transcription. A fragment comprising approximately 6 kb of sequence upstream of the FRNK ATG (Ϫ5388 to ϩ876) was previously shown to drive SM-specific expression of LacZ in vivo in a pattern reminiscent of FRNK expression. 14 Importantly, we found that the corresponding FRNK promoter attached to a luciferase reporter (FRNK-Luc) exhibited high activity in cultured SMCs in comparison to 10T1/2 cells (consistent with the levels of FRNK expressed in these two cell types; supplemental Figure IIB ). Although FRNK is expressed in a SM-restricted fashion, careful analysis of the FRNK promoter region from chicken, mouse, and human sequence did not reveal any conserved CArG elements, known to direct SRF-dependent transcription. Indeed, coexpression of SRF and FRNK-Luc in SRF Ϫ/Ϫ ES cells did not alter basal FRNK-Luc promoter activity in these cells, whereas reconstitution of SRF induced expression of a SM␣actin-Luc construct approximately 15-fold ( Figure 2A ). Moreover, when expressed in SMCs, the FRNK-Luc construct was unresponsive to overexpression of the myocardin family of SRF cofactors, which stimulated strong activation of the SM␣-actin-Luc reporter (supplemental Figure IIC) . Furthermore, ectopic expression of myocardin did not alter FRNK message levels but induced a striking 60-fold increase in SM22 message ( Figure  2B ). Collectively, these data provide strong support for FRNK being expressed in a non-SRF/CARG dependent fashion as previously suggested. 22 We next screened a number of cytokines/growth factors known to be released after vessel injury for their ability to increase FRNK promoter and protein levels in cultured rat aortic SMCs. We found that TGF-␤ induced a marked increase in FRNK-Luc activity, FRNK mRNA (as assessed by quantitative RT-PCR), and protein levels compared to vehicle-treated cells ( Figure 2C through 2E), whereas other agonists including the potent SMC mitogens PDGF-BB, S1P, angiotensin II, thrombin, and basic-fibroblast growth factor had no effect (data not shown). The ability of SB 431542 (a selective inhibitor of the TGF-␤1 activin receptor-like kinase; ALK-5) to dramatically reduce expression of FRNK in cultured SMCs under serum-starved conditions or after TGF-␤ treatment strongly supports the idea that TGF-␤ is a major regulator of FRNK expression ( Figure 2E ).
Because TGF-␤ induces FRNK expression and SM differentiation, we theorized that FRNK might promote SMC phenotypic switching from a synthetic to contractile state. To directly explore this possibility, we performed SMC promoter-reporter assays in 10T1/2 cells, a multi-potential SMC precursor line that has been shown to markedly upregu-late SMC-specific gene expression on stimulation with serum, S1P, or TGF-␤. 19, 20 Whereas FRNK protein is not expressed in detectible levels in 10T1/2, FRNK message is detectible by quantitative RT-PQR (data not shown) and forced expression of FRNK in these cells inhibited FAK activity and resulted in a 2-to 4-fold increase in SM22, SM␣-actin, and SM-MHC promoter activity, without effecting myocardin levels ( Figure 3A ; supplemental Figure IIIA and IIIB). We reasoned that FRNK expression likely promotes SMC differentiation by relieving FAK-dependent repressive signals. To determine whether FAK activation limits SM marker gene expression we ectopically expressed a constitutively active FAK variant (termed SuperFAK 21 ) that leads to enhanced FAK activity as assessed by phosphorylated Y397 FAK levels. As expected, SuperFAK expression in 10T1/2 cells significantly reduced SM22 ( Figure 3B ) and SM␣-actin reporter gene expression (supplemental Figure  IIIC) . Similarly, ectopic expression of FRNK and FAK variants in primary rat aortic SMC revealed an inverse relationship between FAK activity and SM gene expression (ie, low FAK activity correlates with high levels of SM markers, Figure 3C ; supplemental Figure IIID ). Taken together, our findings provide compelling evidence that FAK activity limits SMC differentiation, and upregulation of FRNK promotes differentiation by attenuating FAK activity.
We next examined TGF-␤-stimulated SM gene expression in our cell culture models. We found that TGF-␤ and FRNK acted in concert to induce SM22 reporter activity in 10T1/2 cells ( Figure 3D ). Importantly, similar results were observed when we analyzed endogenous SM gene expression by Western analysis. SM22 protein was undetectible in 10T1/2 cells under basal conditions, but either expression of FRNK or treatment of cells with TGF-␤ for 48 hours induced a modest increase in SM-22, and when combined, these agents markedly increased SM22 expression ( Figure 3E ). FRNK and TGF-␤ each individually led to a similar marked induction of SM␣-actin protein levels in 10T1/2 cells, however the combined treatment had a more modest effect, most likely because of the already high levels of SM␣-actin induced by each factor alone. Collectively, these data provide support for a model whereby TGF-␤ induces FRNK expression and that FRNK, in turn, contributes to TGF-␤-induced SMC differentiation by dampening FAK-dependent signals.
We next strove to evaluate FRNKs function to regulate SMC phenotype in postnatal vessels. FRNK Ϫ/Ϫ mice were recently generated by a strategy that resulted in deletion of a 1-kb fragment that included the noncoding exon and 700 bp of upstream fak intronic sequence (see schematic in Figure  1A ). Although these mice were born in the expected Mendelian frequency and showed no gross phenotype, they were not specifically examined for defects in SMC differentiation marker gene expression or growth. 14 Because the timing of FRNK expression during development and following vascular injury correlates with the conversion of SMC from a synthetic to contractile phenotype 15 we first examined the proliferation index of medial SMC in postnatal vessels from wild-type or FRNK Ϫ/Ϫ mice. As shown in Figure 4A , medial SMC in postnatal FRNK Ϫ/Ϫ vessels exhibit a significantly higher index of BrdU incorporation in comparison to littermate control vessels. Importantly, SMC tissue from postnatal FRNK Ϫ/Ϫ pups reveal lack of FRNK protein and higher levels of active p Y397 FAK, in comparison to wild-type littermate controls, whereas total FAK protein levels are unaltered ( Figure 4B ).
We next analyzed the dynamic expression of the contractile genes, SM␣-actin, SM-22, and smoothelin B in the aorta of postnatal control and FRNK Ϫ/Ϫ mice by quantitative RT-PCR. Expression of these contractile genes is enhanced approximately 6-to 10-fold from 4 day postnatal to adult vessels in wild-type mice (data not shown). Interestingly, we found that FRNK Ϫ/Ϫ vessels contain significantly fewer transcripts of these genes in the 2-to 3-week period of vessel development when compared to age and littermate controls, when FRNK protein is most highly abundant in wild-type vessels ( Figure 4C ). 12 However, no significant differences in SM marker gene expression were observed in adult aorta (see data for 8-week animals in Figure 4C ) or carotid vessels isolated from wild-type or FRNK Ϫ/Ϫ mice ( Figure 5A) , indicating that the lag in SM differentiation observed in the neonatal vessels was normalized during vessel maturation. In spite of these transient significant differences in SMC phenotype, we did not detect any significant difference in medial thickness of FRNK Ϫ/Ϫ adult arterioles (aorta or carotids) in comparison to littermate control vessels analyzed from 7 days postnatal to adult (supplemental Figure IV) . Also, we found that adult FRNK Ϫ/Ϫ mice did not exhibit significant changes in mean systolic blood pressure (as assessed by tail cuff measurements) or pressor responses (as assessed by intraaortic catheterization) after phenylephrine treatment in comparison to wild-type littermate controls (supplemental Figure  IV) , indicating that FRNK expression does not function to regulate vascular homeostasis in adult mice (see Supplemental Data section for further discussion).
Because we previously reported that FRNK expression is relatively low in adult vessels, but is dramatically upregulated by 14 days after catheter-induced vessel injury, we postulated that FRNK might also regulate SMC phenotypic switching during restenosis. Numerous studies have revealed that contractile gene expression is dynamically regulated after vascular injury induced by either vessel ligation or surgical endothelial denudation. Typically, reduced SMC marker gene expression is apparent within 3 to 7 days after injury followed by a burst of reexpression after approximately 2 to 3 weeks. 17, 18 To examine a possible involvement of FRNK in the regulation of SMC redifferentiation after vascular injury, we performed quantitative RT-PCR for SM marker genes in wild-type and FRNK Ϫ/Ϫ carotid arteries 7 to 21 days after carotid ligation. As shown in Figure 5 , significant decreases in reexpression of SM␣-actin, SM-22, and smoothelin B (but not ␤-actin) were observed in FRNK Ϫ/Ϫ vessels in comparison to littermate controls, indicating that the recovery of SM differentiation was defective in injured FRNK Ϫ/Ϫ arteries. Notably, no significant differences in SM gene expression were observed in the control unligated right carotid artery at the time points examined (data not shown). Concomitantly, immunohistochemical analysis for SM␣-actin revealed a striking difference between wild-type and FRNK Ϫ/Ϫ vessels 14 days after ligation. Although robust SM␣-actin staining was observed throughout the media and neointima of wildtype vessels, SM␣-actin expression in the neoinitma of FRNK Ϫ/Ϫ vessels was markedly reduced ( Figure 5D ). Al-though we anticipated that this phenotype might lead to a more exacerbated injury response, morphometric analysis at this time point revealed no significant differences in the extent of remodeling induced by ligation of wild-type and FRNK Ϫ/Ϫ vessels, likely because of the fact that the ligation induces a very strong proliferative response in the wild-type mice (supplemental Figure V) . Indeed, by 21 days after ligation full occlusion of injured vessels was observed in both wild-type and FRNK Ϫ/Ϫ mice. Collectively, these data provide strong support for the hypothesis that upregulation of FRNK expression after vessel injury is required for appropriate SMC maturation that occurs subsequent to injury repair.
Finally, we used cultures derived from FRNK Ϫ/Ϫ mice to confirm our previous in vitro and in vivo findings. We found that aortic SMC isolates from FRNK Ϫ/Ϫ mice consistently exhibited enhanced p Y397 FAK, and lower levels of the contractile proteins SM22, SM␣-actin, and SM-MHC than SMC isolates from aged matched (and passage-matched) control mice ( Figure 6A ), while these cells maintained similar morphology (supplemental Figure VI) . The low levels of SMC proteins in FRNK Ϫ/Ϫ SMCs may reflect the inability of these cells to maintain a differentiated phenotype in these progrowth culture conditions (see online Supplemental Data section for further discussion). In support of the notion that FRNK acts to enhance TGF-␤ dependent gene expression, we found that TGF-␤-induced expression of endogenous SM22 was significantly decreased in FRNK Ϫ/Ϫ SMCs in comparison to matched wild-type SMC isolates ( Figure 6B ). We also noticed that the FRNK Ϫ/Ϫ cells exhibited high growth rates and were more motile than control SMC isolates (data not shown). To directly test that these differences were attributable to lack of FRNK expression, we next reconstituted FRNK in FRNK Ϫ/Ϫ cells. As shown in Figure 6C through 6E, reexpression of FRNK in these cultures significantly in- creased SM␣-actin expression, but significantly decreased both BrdU incorporation and PDGF-stimulated motility.
Discussion
FRNK, a dominant interfering mutant that attenuates FAK activity, exhibits selective and dynamic expression in SMCs. We previously reported that FRNK attenuates SMC proliferation and migration by regulating FAK/Rac1-dependent signaling. 23 Herein we have found an additional function for FAK/FRNK signaling in SMCs. We present evidence that FRNK deletion (by homologous recombination) represses SM gene expression during postnatal vessel growth and following vascular injury. We also show that FRNK expression is regulated by TGF-␤ and that forced expression of FRNK induces SM marker gene expression in cultured cells grown in serum and enhances TGF-␤-stimulated SM marker gene expression. Conversely, FRNK deletion or expression of a constitutively activated FAK variant attenuated SM gene transcription. These data suggest that enhanced FAK activity is permissive for SMC growth and migration, but limits SM differentiation, and that tight regulation of FAK activity is likely important for proper SMC phenotypic modulation during development and following vascular injury.
FAK is activated by a process that involves dimerization and intermolecular phosphorylation of tyrosine 397 in trans. 24 Phosphorylation of Y397 results in subsequent recruitment of the tyrosine kinase Src (or Fyn), which phosphorylates and further activates FAK (and phosphorylates certain FAK binding partners). 11 FRNK likely attenuates FAK activity by inducing the formation of FRNK/FAK heterodimers that are incapable of Y397 phosphorylation and Src binding. In support of this notion, expression of wild-type FAK (and Src) can rescue FRNK-dependent inhibition of FAK (and paxillin) phosphorylation, whereas expression of a phospho-deficient Y397F FAK cannot. 25 Our findings indicating that FAK activity is enhanced in tissues and cells derived from FRNK Ϫ/Ϫ mice strongly supports the hypothesis that the dynamic regulation of FRNK expression can impart specific spatial and temporal control of FAK activity in vivo. In this regard, it is interesting to note that FAK protein is extremely stable with a reported half-life exceeding 20 hours, 26 whereas we found that FRNK protein turnover is rapid. We speculate that transient FRNK expression is particularly important in the vasculature, where direct apposition of SMCs with extracellular matrix could lead to high levels of FAK activation and uncontrolled SM growth. It is feasible, however, that FRNK has additional FAK-independent functions, and future studies will examine this possibility.
In support of the idea that FRNK/FAK signaling plays an active role in regulating smooth muscle cell phenotypes, FAK Ϫ/Ϫ mouse embryonic fibroblasts were recently reported to exhibit a myo-fibroblast appearance as assessed by high levels of SM ␣-actin containing stress fibers relative to control fibroblasts. 27 Interestingly, we recently found that FAK-deficient SMC (like FRNK overexpressing SMC) exhibit enhanced TGF-␤ stimulated SM marker gene expression (Sayers RL, Sundberg-Smith LJ, Mangiante LE, Beggs HE, Reichardt LF, Schwartz RJ, Mack CP, Taylor JM, 2008, unpublished observations; see Supplemental Data section for further discussion). In addition, recent studies have provided evidence for a role of FAK in promoting striated muscle cell differentiation as the dynamic regulation of FAK activity was found to be essential for differentiation of C2C12 myoblasts into myotubes. 28 Also, a role for FAK in the promotion of cardiogenesis was suggested by studies in which stable expression of FRNK in ES cells was shown to induce cardiac ␣-myosin heavy chain and sarcomeric myosin expression. 29 Because SRF plays a critical role in the regulation of contractile gene expression in each of these muscle types, it will be of future interest to determine whether limiting FAK activity regulates SRF activity or cofactor recruitment.
Because FRNK exhibited a striking SMC-restricted expression pattern, we sought to explore the mechanisms underlying its transcriptional regulation. Interestingly, we found that the FRNK promoter does not contain a canonical CArG box, is not affected by SRF deletion, and is unresponsive to overexpression of the myocardin family of potent SRF cofactors. Thus, FRNK belongs to a subclass of smooth muscle specific genes that are regulated in a CArGindependent fashion including aortic carboxypeptidase-like protein (ACLP), cysteine-rich protein 2 (CRP2), and histidine-rich calcium-binding protein (HRCBP) (see Supplemental Data for further discussion). 30 -32 Interestingly, TGF-␤, a strong activator of SMC differentiation, led to significant upregulation of FRNK expression. Thus, future exploration of the TGF-␤-dependent mechanisms that control FRNK expression may lead to identification of additional transcription factors that regulate SMC phenotypes.
Although reported to affect a wide variety of cellular processes a principal function for FAK in numerous cell types is its ability to modulate integrin and growth factor receptorstimulated cellular migration. 11 Direct evidence for the role of FAK in modulating fibronectin-dependent motility was previously shown using FAK Ϫ/Ϫ fibroblasts, endothelial cells, neurons, and keratinocytes. [33] [34] [35] [36] We previously showed that FRNK expression in SMCs attenuated FAK-dependent PDGF-stimulated chemotaxis, 12 and our recent studies reveal that FAK Ϫ/Ϫ SMCs exhibit a similar defect (Sayers RL, Sundberg-Smith LJ, Mangiante LE, Beggs HE, Reichardt LF, Schwartz RJ, Mack CP, Taylor JM, 2008, unpublished observations) . Because FRNK appears to play a dual role in SM function, aiding to block SMC growth and migration and to promote SMC differentiation, FRNK may function as a toggle in the regulation of SMC phenotypes.
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